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Abstract
Introduction The breast microenvironment can either retard or
accelerate the events associated with progression of latent
cancers. However, the actions of local physiological mediators
in the context of breast cancers are poorly understood.
Serotonin (5-HT) is a critical local regulator of epithelial
homeostasis in the breast and other organs. Herein, we report
complex alterations in the intrinsic mammary gland serotonin
system of human breast cancers.
Methods Serotonin biosynthetic capacity was analyzed in
human breast tumor tissue microarrays using
immunohistochemistry for tryptophan hydroxylase 1 (TPH1).
Serotonin receptors (5-HT1-7) were analyzed in human breast
tumors using the Oncomine database. Serotonin receptor
expression, signal transduction, and 5-HT effects on breast
cancer cell phenotype were compared in non-transformed and
transformed human breast cells.
Results In the context of the normal mammary gland, 5-HT acts
as a physiological regulator of lactation and involution, in part by
favoring growth arrest and cell death. This tightly regulated 5-HT
system is subverted in multiple ways in human breast cancers.
Specifically, TPH1 expression undergoes a non-linear change
during progression, with increased expression during malignant
progression. Correspondingly, the tightly regulated pattern of 5-
HT receptors becomes dysregulated in human breast cancer
cells, resulting in both ectopic expression of some isoforms and
suppression of others. The receptor expression change is
accompanied by altered downstream signaling of 5-HT
receptors in human breast cancer cells, resulting in resistance
to 5-HT-induced apoptosis, and stimulated proliferation.
Conclusions Our data constitutes the first report of direct
involvement of 5-HT in human breast cancer. Increased 5-HT
biosynthetic capacity accompanied by multiple changes in 5-HT
receptor expression and signaling favor malignant progression
of human breast cancer cells (for example, stimulated
proliferation, inappropriate cell survival). This occurs through
uncoupling of serotonin from the homeostatic regulatory
mechanisms of the normal mammary epithelium. The findings
open a new avenue for identification of diagnostic and
prognostic markers, and valuable new therapeutic targets for
managing breast cancer.
Introduction
Evolution in cancers is a convergent phenomenon, during
which heterogeneous genetic and epigenetic changes lead to
similar ultimate tumor phenotypes. The essential phenotype of
epithelial cancers (e.g., breast, liver, pancreas, prostate, and
so on) includes: self-sufficiency for growth signals, insensitivity
to growth inhibition, evasion of programmed cell death, appar-
ently limitless replicative potential, sustained angiogenesis,
5-HT: 5-hydroxytryptamine, serotonin; 5-HT7: type 7 serotonin receptor protein; ATCC: American Type Culture Collection; BSA: Bovine Serum Albu-
min; DMEM: Dulbecco's Modified Eagle Medium; EGF: Epidermal Growth Factor; ER: Estrogen Receptor; FBS: Fetal Bovine Serum; HRP: Horse-
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Cells; PR: Progesterone Receptor; RT-PCR reverse-transcriptase-couple polymerase chain reaction; SERT: serotonin transporter protein; TPH1: 
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and tissue invasion [1-4]. The convergent evolution of cancer
phenotypes presents numerous prevention and treatment
challenges because of the ability of cancer cells to exploit a
variety of normal physiological processes out of context. In this
study, we report extensive modifications of the recently-dis-
covered mammary serotonin (5-hydroxytryptamine, 5-HT) sys-
tem [5-9] in human breast cancers. This is the first account
illustrating direct involvement of 5-HT in breast cancers, and
shows that an important homeostatic signal is subverted by
cancer cells, yielding paradoxical effects on growth and apop-
tosis.
Serotonin is a monoamine hormone and neurotransmitter that
has been evolutionarily conserved, with functions stretching
across the animal and plant phyla [10]. Although parochially
known and studied as a neurotransmitter, with critical cogni-
tive and behavioral functions in humans, 5-HT has numerous
important peripheral functions in the gut, vasculature, immune
system, and at wound sites [11-16]. Serotonin is synthesized
in a two-step reaction from the amino acid L-tryptophan. The
first and rate-limiting step in 5-HT synthesis is catalyzed by
tryptophan hydroxylase (TPH), which is represented by neuro-
nal (TPH2) and non-neuronal (TPH1) isoforms. Serotonin
exerts its actions through a repertoire of greater than 15 differ-
ent receptor proteins, belonging to seven discreet families. Six
of the families of 5-HT receptors are G-protein-coupled,
including Gi: 5-HT1, Gs: 5-HT4,6,7, and Gq/11: 5-HT2,5. 5-HT3 is
uniquely a ligand-gated cation channel, related to the nicotinic
acetylcholine receptor. Another major player within the 5-HT
system is the 5-HT reuptake transporter (SERT), which is
involved in the uptake and clearance of extracellular 5-HT.
Mammary epithelial homeostatic mechanisms ensure normal
tissue function during dramatic changes associated with preg-
nancy, lactation and involution. Serotonin is an integral part of
this epithelial homeostatic system. In part, breast cancers arise
through dysregulation of epithelial homeostatic systems
[17,18].
Regulation of epithelial homeostasis by 5-HT is not exclusive
to the mammary epithelium. Serotonin has been implicated in
epithelial homeostasis of the lung, pancreas, liver and pros-
tate. Moreover, dysregulation of 5-HT systems in these epithe-
lia are associated with various pathologies, including cancer
progression [19-29]. Consequently, alteration of local 5-HT
signaling may be a common feature of cancer progression in
epithelial tumors.
In these studies, we present the first analysis of the mammary
5-HT system in human breast cancer. Our results show exten-
sive 5-HT signal modifications contributing to the cancer phe-
notype. These results provide a new theoretical framework for
studying 5-HT signaling in a variety of epithelial cancers.
Materials and methods
Subjects
Primary human mammary epithelial cells (pHMEC), obtained
from reduction mammoplasty under Institutional Review Board
approval, were a generous gift from Eric R. Hugo at The Uni-
versity of Cincinnati; cell lines and anonymous tissue microar-
ray specimens purchased from the National Cancer Institute
were considered to be exempt. The research carried out in this
article is in compliance with the Declaration of Helsinki.
Cells and media
Primary human mammary epithelial cells (pHMEC) were pre-
pared using a modification of previously described protocol
[30]. Briefly, excised human mammary tissue was finely
minced, transferred to conical tubes, and digested overnight
at 37°C in M199 media containing 2.5 mg/ml BSA (Sigma-
Aldrich, St. Louis, MO, USA), 0.1% collagenase type III (Wor-
thington Biochemical Corporation, Lakewood, NJ, USA) and
antibiotic-antimycotic (Invitrogen, Carlsbad, CA, USA).
Digested tissue was pelleted by centrifugation, washed in
phosphate buffered saline (PBS), and either plated in the
pHMEC media (see below) or frozen back for later use.
All the cell lines used in the aforementioned studies were pro-
cured from the American Type Culture Collection (ATCC), and
used within 10 passages after acquisition. MCF10A media
consisted of the following: DMEM-F12 50:50 (Invitrogen) sup-
plemented with 5% horse serum, 2 mM L-glutamine, 10 μg/ml
insulin (Sigma-Aldrich), 20 ng/ml EGF (Upstate Biotechnol-
ogy, Waltham, MA, USA) 0.5 μg/ml hydrocortisone and antibi-
otic/antimycotic (Invitrogen). pHMEC media contained
DMEM-F12 50:50, 5% FBS (Hyclone, Logan, UT, USA), insu-
lin (Sigma-Aldrich), hydrocortisone (Sigma-Aldrich), EGF
(Upstate), 1 ng/ml cholera toxin (Sigma-Aldrich) (except
where noted) and antibiotic-antimycotic (Invitrogen). MDA-
MB-231 cells were cultured in DMEM (Invitrogen) supple-
mented with 10% FBS, L-glutamine and antibiotic-antimycotic
(Invitrogen). T47D cells were grown in same media as MDA-
MB-231 with the addition of 5 μg/ml of insulin. MCF7 cells
were grown in media consisting of DMEM-F12 50:50 (Invitro-
gen) supplemented with 10% FBS, L-glutamine, 1 mM sodium
pyruvate (Invitrogen), 1× concentration of non-essential amino
acids (Invitrogen), and antibiotic-antimycotic (Invitrogen).
Immunohistochemistry and immunofluroscence
Paraformaldehyde fixed paraffin embedded mouse mammary
gland sections and tissue microarray sections were depar-
affinzed in xylene and rehydrated in decreasing concentrations
of ethanol from 100% to 50%. Endogenous peroxidases were
blocked by incubation in 3% H2O2 at room temperature for 30
min. Antigen retrieval was performed using borate buffer pH =
8.5 (80 mM boric acid, 20 mM sodium borate) in a microwave
(60% power) twice for 5 min. Sections were then permeabi-
lized using 0.2% Triton X-100 (Sigma-Aldrich) in PBS for 30
min followed by normal serum blocking for 1 h at room temper-Available online http://breast-cancer-research.com/content/11/6/R81
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ature and incubation in primary antibody (sheep anti-TPH
1:100 Abcam, Cambridge, MA, USA) overnight at 4°C in a
humid chamber. The immune reaction was visualized using
HRP-conjugated secondary antibody (Sigma-Aldrich) and
ABC-DAB system (Zymed, S. San Francisco, CA, USA; and
Vector Labs, Burlingame, CA, USA, respectively).
Cells grown on coverslips were fixed in 4% paraformaldehyde.
Cells were permeabilized in 0.1% Triton X-100, incubated in
borate buffer overnight at 75°C and incubated in primary anti-
bodies overnight at 4°C. Images were collected using a Zeiss
LSM510 Confocal Microscope, Göttingen, Germany) using
the Zeiss LSM Image Software version 3.5, Munich, Germany)
RT-PCR and Western blot
Total cellular RNA was extracted using TRI-REAGENT (Molec-
ular Research Center, Inc., Cincinnati, OH, USA) according to
the manufacturer's instructions. Two μg of RNA was sub-
jected to reverse transcription by standard methods. One μl
cDNA was used for 25 μl PCR reactions. For primer informa-
tion, please see Table S1 in Additional data file 1.
Cellular protein extracts were prepared using the Cell Lysis kit
(Cell Signaling Technology, Boston, MA, USA) as per the
manufacturer's instructions. Proteins were quantified using
Lowry assay and equal amounts were separated on SDS-
PAGE gel. After transferring the proteins to nitrocellulose
membrane, the specific proteins were visualized using specific
antibodies and detected using HRP tagged secondary anti-
bodies.
Proliferation assay and Trypan blue assay
After experimental treatments, cell proliferation was measured
by colorimetric assay based on cleavage of a tetrazolium salt
3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
sulfophenyl)-2H-tetrazolium (MTS) by mitochondrial dehydro-
genase enzyme present in proliferating cells (Cell titer 96 -
Promega, Madison, WI, USA). For trypan blue experimental
procedures, the cells were gently trypsinized and re-sus-
pended in 0.2% trypan blue solution and counted using a
hemocytometer.
Tissue microarray
Human breast cancer tissue microarrays were purchased from
The National Cancer Institute (Bethesda, MD, USA [31]. The
array has 288 cores in quadruplicate with tissue matched con-
trols. A modified histochemical-score (H-score) [32,33] sys-
tem was used to evaluate the breast cancer tissue
microarrays. An H-score comprises of a semi-quantitative
assessment of both the intensity of staining and percentage of
positive mammary epithelial cells. For intensity, a score of 0 to
3, corresponding to negative, weak, positive and strong posi-
tive was recorded blindly by two independent observers with
final scores resulting in an average. It was not necessary to
correct the staining intensities to account for the percentage
of positive cells because of uniform epithelial staining within
given specimens.
Statistics
Each experiment in cultured cells and tissues was replicated
three or four times, and representative results are shown in fig-
ures. Differences in means were tested by ANOVA with
Tukey's post-hoc test for multiple groups, and Student's T-test
or an equivalent non parametric test (Mann-Whitney U test) for
comparisons of two means. Significance was accepted for P
< 0.05.
Results
Elevated TPH1 in human breast cancer cells
TPH1 catalyzes the first and the rate-limiting step in 5-HT bio-
synthesis. We have previously shown that TPH1 is expressed
in the mammary gland and TPH1 expression directly correlates
with 5-HT production [5,6]. We therefore addressed the ques-
tion of whether there were any changes in 5-HT synthetic
capacity of breast cancer cells. Toward this end, we analyzed
TPH1 mRNA levels by reverse-transcriptase-couple polymer-
ase chain reaction (RT-PCR) in different human breast cancer
cells (MCF7, MDA-MB-231 and T47D), and compared them
to that of non-transformed human mammary epithelial cells
(MCF10A). The mRNA levels of TPH1 were elevated more
than two-fold in MDA-MB-231 and T47D cells compared to
that of MCF10A cells (Figure 1A). The TPH1 protein was ana-
lyzed by western blot in extracts of these cells and was signif-
icantly elevated not only in MDA-MB-231 and T47D, but also
in MCF7 cells, demonstrating that 5-HT biosynthetic capacity
was increased in all breast cancer cell lines tested, with the
highest level of expression occurring in MDA-MB-231 cells
(Figure 1B). This was contrary to what occurred in MCF10A
cells, where TPH1 protein was near the lower limit of detection
by western blotting (Figure 1B). An additional factor that reg-
ulates cellular exposure to 5-HT is SERT, which pumps 5-HT
back into the cells contributing to the recycling and controlling
the extracellular concentration of 5-HT. We assessed SERT
protein levels and found them to be similar among these cell
lines [see Figure S1 in Additional data file 1].
Nonlinear association of TPH1 with breast cancer 
progression
To gain insight into the possible association between altered
5-HT synthesis and breast cancer progression in actual human
tumors, we analyzed TPH1 in histological specimens. The
specimens used were human breast cancer tissue microarrays
acquired from The National Cancer Institute Cooperative
Breast Cancer Tissue Resource [31]. Quadruplicate samples
of 288 cores comprised the array, which included both tissue-
matched non-cancer and non-diseased controls, along with
cell line controls. Figure 2A shows a representative section of
normal human breast tissue from an array at two different mag-
nifications, stained for TPH1. In normal breast tissue the epi-
thelium was dispersed in an orderly fashion within the stroma,Breast Cancer Research    Vol 11 No 6    Pai et al.
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and the epithelium stained distinctly for TPH1. Scattered
blood vessel-associated cells were also positive for TPH1
within the stroma. A modified H-score [34,35] was used by
blinded examiners to score the stained tissues. Sections were
scored on a scale of 0 to 3 with respect to TPH1 staining sep-
arately within epithelia and stroma, using a key generated from
among the array sections [see Figure S2 in Additional data file
1]. Cores of cell lines on the array (MCF7 and T47D) validated
the scoring for TPH1. Similar to the expression pattern we had
seen previously in the cell lines (Figure 1), TPH1 staining inten-
sity was significantly elevated in the cancer cell lines, com-
pared with normal breast tissue (Figure 2B).
The tissue specimens on the array were all from primary tumor
sites, and were scored based on a variety of pathological cri-
teria. An obvious and clinically meaningful characterization is
reproductive steroid receptor (estrogen receptor (ER) and
progesterone receptor (PR)) status. Levels of TPH1 were
lower in ER negative cases, compared with ER positive cases.
There was no difference in TPH1 levels associated with PR
status of the breast cancers (Figure 2C and 2D, respectively).
Segregating the cases crudely according to tumor size and
according to T-stage (another size-based classification)
showed an inverse relationship between tumor size (>20 mm)
and TPH1 staining [see Figure S3 in Additional data file 1].
When the breast cancer cases were sorted according to inva-
sion and progression criteria, TPH1 staining showed a set of
nonlinear relationships (Figure 3). Staining for TPH1 was
lower in locally-invasive (IN+) cases compared with non-inva-
sive samples (NI), which included both normal tissue and duc-
tal carcinoma in situ (DCIS). However, TPH1 was high in
cases of tumors with distant metastases (IN-Mets) (Figure
3A). The relationship of TPH1 staining to progression was
clearest among samples sorted according to N-stage (extent
of lymph node involvement) (Figure 3B). Staining for TPH1
was significantly decreased in the N1 staged tumors (one to
three ipsilateral nodes). However, with progression to N1a/b
stage (micrometastases to four or more nodes, including
extension beyond the node capsule) and higher stages (N2/3),
the TPH1 staining was elevated. Representative core sections
from each sorted category are depicted in Figure 3C.
5-HT receptor expression in association with breast 
cancer progression
To determine the expression of 5-HT receptor mRNA profiles,
we performed a comprehensive analysis by RT-PCR (Figure
4). In addition to HTR7, which has been studied in detail in the
breast [6,7], we report for the first time the expression of
HTR1D, 2B and 3A in an untransformed cell line and primary
human mammary epithelial cells (MCF10A and pHMEC) (Fig-
ure 4). The HTR1D and 2B were also present in all breast can-
cer cells tested and, using human hypothalamus as the
reference level, expression in the cancer cells was elevated
compared to the untransformed cells (Figure 4Bi and 4Biv).
Among the receptor isoforms that were expressed differen-
tially in breast cancer cell lines, HTR3A was markedly down-
regulated in all of the cancer lines (Figure 4A and 4Bvi). Three
receptor types were upregulated in MCF7 to levels that were
Figure 1
TPH1 expression in non-transformed and breast cancer cells TPH1 expression in non-transformed and breast cancer cells. (A) Bar graphs representing TPH1 mRNA levels in indicated cell lines as detected by 
semi-quantitative RT - PCR reactions and normalized to GAPDH. Shown below is a representative picture of resulting PCR reactions. (B) Bar 
graphs and electophoretic bands showing TPH1 protein levels in the extracts of indicated cells normalized to β-actin. Error bars in (A) and (B) repre-
sent ± SEM. *P < 0.05, **P < 0.01 and ***P < 0.001 (one-way ANOVA) in comparison to MCF10A cells.Available online http://breast-cancer-research.com/content/11/6/R81
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at least 40% of the brain (1E, 1F, 2C) (Figure 4A, Bii, iii and
4Bv). MDA-MB-231 expressed 1F, and T-47D expressed both
1F and 2C at modest levels relative to the brain (Figure 4B).
No detectable transcripts for HTR1A, 1B, 2A, 4, 5A and 6
were found in the untransformed (MCF10A and pHMECs) or
breast cancer cells (MCF7, T47D and MDA-MB-231) (Figure
4A) and [see Figure S4 in Additional data file 1]. HTR7 was
expressed in MCF10A [6,7], pHMEC and MDA-MB-231 cells.
In contrast, MCF7 and T47D, both of which are ER positive
cancer cells, lacked any detectable HTR7 transcript (Figure
4A).
To address the question of 5-HT receptor profiles in breast
cancers, we examined expression using the Oncomine data-
Figure 2
Changes in TPH1 signal in human breast tumors Changes in TPH1 signal in human breast tumors. (A) Representative image of normal human breast tissue (BT) from the tissue microarray stained 
for TPH1 (brown) and counterstained with hematoxylin. A corresponding no primary antibody control section is depicted on the bottom left. Magni-
fied image shows details of epithelial staining and occasional positive cells in stroma. (B-D) Results depicting quantification of TPH1 immunostain-
ing from blindly scored tissue microarray sections. The section scores for TPH1 were sorted as per human cancer cell line core (B), estrogen 
receptor (ER) status (C) and progesterone receptor (PR) status (D). TPH1 staining was reduced in ER negative tumors, but unaffected by PR status. 
Error bars represent ± SEM. *P < 0.05 in comparison with normal BT for (A).Breast Cancer Research    Vol 11 No 6    Pai et al.
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base [36,37] to search preliminarily for patterns of 5-HT
receptor gene expression (Table 1). Among all of the receptor
isoforms, HTR1B, 1D, 1F, 2A, 2B, 2C, 3, 4, 5A, 7 were found
to be expressed in breast tissues (cancer and other). Of these
receptors, the expression levels of HTR1D, 2A and 3 were
unchanged in the archived studies (data not shown). The
HTR1D pattern was in accord with the breast cancer cell lines
(Table 1). HTR1B and 2A were not expressed in either
pHMEC or established breast cell lines (Figure 4), which
implies that expression in tumor specimens represents the
presence of stromal or vascular elements, which typically
express HTR1B and 2A in smooth muscle cells [38,39].
A significant subset of 5-HT receptor mRNAs (HTR1F, 2B, 4
and 7), were significantly decreased in ER negative tumors,
relative to ER positive tumors (Table 1). These observations
Figure 3
Nonlinear association between TPH1 and cancer progression Nonlinear association between TPH1 and cancer progression. (A-B) Results depicting quantification of TPH1 immunostaining from blindly scored 
tissue microarray sections. Data were sorted based on the indicated criteria. Data were analyzed by one-way ANOVA with P-values as noted in com-
parison with NI for (A) and N0 for (B). Error bars represent ± SEM. (A) TPH1 scores in samples identified as non-invasive (NI); invasive, node-nega-
tive (IN-); invasive, node-positive (IN+); and invasive with distant metastases (IN-Mets). (B) Human breast cancer tissue sections scored for TPH1 
were sorted as per different stages of nodal metastasis (N-stage: N0, no regional lymph node involvement; N1, Mets to movable ipsilateral nodes; 
N1a/b, Mets up to 20 mm to 4 or more nodes with extension beyond node capsule; N2-3, Mets to ipsilateral nodes that are fixed to one another or 
to other structures and to internal mammary lymph nodes). (C) Representative microarray sections stained for TPH1 from sorted groups as indicated 
below each image. Brown/red dye indicates TPH1 stain, blue is hematoxylin.Available online http://breast-cancer-research.com/content/11/6/R81
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Figure 4
Difference in 5-HT receptor isoform gene expression between non-transformed (pHMECs and MCF10A) and breast cancer cells (MCF7, MDA-MB- 231 and T47D) Difference in 5-HT receptor isoform gene expression between non-transformed (pHMECs and MCF10A) and breast cancer cells (MCF7, MDA-MB-
231 and T47D). (A) Representative RT-PCR reactions (mRNA transcripts) for indicated 5-HT receptors, in cells as indicated at the top. Human brain 
(hypothalamus) is used as a reference sample for each receptor. For primer information please see Table S1 in Additional data file 1. (B) Densito-
metric quantification (semi-quantitative) of transcript levels relative to human brain reference samples (100%). Each column represents average with 
error bars representing ± SEM of at least three independent reactions.Breast Cancer Research    Vol 11 No 6    Pai et al.
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were confirmed by multiple independent studies. HTR2B
expression was also lower in basal tumors (ER negative), com-
pared with luminal tumors, which are most commonly ER pos-
itive (Table 1).
Expression levels for HTR1F, 2B, 2C, 5A and 7 showed overall
increases in breast cancers. HTR2B, which is expressed in
untransformed human mammary epithelium (Figure 4), was
elevated in carcinomas and was found to increase with tumor
stage, and concomitantly was higher in lymph node-positive
tumors as compared to node-negative tumors (Table 1). This
observation was supported by a study of HMECs, showing c-
Myc transformation induced an increase in HTR2B expression
(Table 1). Similar to HTR2B, HTR2C showed an increase in
expression with tumor stage. The HTR2C pattern was in
accord with the increased expression observed in human
breast cancer cell lines (Figure 4). Analogously, HTR2C
expression was found to be higher in metastatic and Her2/
neu-overexpressing tumors. The expression of HTR7
increased with tumor grade, and was higher in p53-mutated
tumors (Table 1). This observation also was supported by a
study of HMECs, showing H-Ras transformation induced
increases in HTR7 expression. Other 5-HT receptor expres-
sion changes in breast cancers included HTR1F (higher in
Table 1
Modification of 5-HT receptor expression with human breast cancer status - Oncomine study
Study Type Receptor Type Variable Direction of Change P-value
(T-test)
Oncomine data source
Tumor grade/stage HTR2B Normal vs Breast 
Carcinoma
Higher in Cancer 0.002 Richardson et. al. [77]
Tumor stage N0-N3 Increase with stage 0.006 Bittner et. al. [78]
HTR2C Tumor stage N0-N3 Increase with stage 0.009 Yu et. al. [79]
HTR7 Grade I to III Increase with grade <0.0001 Ivshina et. al. [80]
0.0001 Miller et. al. [81]
<0.01 Ginestier C et. al. [82]
More aggressive vs Less 
aggressive breast cancers
HTR1F 5 yrs recurrence- vs 5 yrs 
recurrence+
Higher in recurring tumors 0.005 VantVeer et. al. [83]
HTR2B Lymph node- vs Lymph 
node+
Higher in lymph node + 0.006 Chin et. al. [84]
HTR2C Primary vs Metastatic 
tumors
Higher in metastatic 0.001 Bittner et. al. [78]
Her2/neu- vs Her2/neu+ Higher in Her2/neu+ 0.00057 Minn et. al. [85]
0.002 Hess KR et. al. [86]
HTR5A P53-mutant vs p53-WT Higher in p53-mutant <0.0001 Miller et. al. [81]
HTR7 P53-mutant vs p53-WT Higher in p53-mutant 0.008 Miller et. al. [81]
Steroid receptor status HTR1F ER+ vs ER- Higher in ER+ 0.0001 Sotiriou et. al. [87]
HTR2B ER+ vs ER- Higher in ER+ 0.00014 Wang et. al. [88]
0.0004 Sotitiou et. al. [87]
0.00014 Desmedt et. al. [89]
Luminal vs Basal Tumors Lower in Basal (ER-) <0.0001 Farmer et. al. [90]
HTR4 ER+ vs ER- Higher in ER+ 0.001 Chi et. al. [84]
HTR7 ER+ vs ER- Higher in ER+ <0.0001 VanderVijer et. al. [91]
0.00087 Bittner et. al. [78]
Human Mammary Cell 
lines
HTR2B HMEC-Normal (GFP) vs c-
Myc transformation
Higher in c-Myc 
transformed cells
0.001 Bild AH et. al. [92]
HTR7 HMEC-Normal (GFP) vs 
activated H-Ras
Higher in H-Ras cells 0.00028 Bild AH et. al. [92]
Receptor mRNAs encoding 5-HT1F (HTR1F), 5-HT2B (HTR2B), 5-HT2C (HTR2C), 5-HT4 (HTR4), 5-HT5A (HTR5A) and 5-HT7 (HTR7) sorted as per 
tumor stage/grade, ER status, tumor aggressiveness and human mammary cell line transformation. Abbreviations: (ER+) - Estrogen Receptor 
Positive, (ER-) - Estrogen Receptor Negative. (HMEC) - human mammary epithelial cells.Available online http://breast-cancer-research.com/content/11/6/R81
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recurring tumors) and HTR5A (higher in p53-mutant) (Table
1).
The variety of examples showing aberrant expression of 5-HT
receptors in breast cancers suggests that multiple modifica-
tions of 5-HT signaling can contribute to the loss of tissue
homeostasis during tumor progression.
5-HT-induced apoptosis and morphological transition
Our previous studies on 5-HT physiology in mammary gland
cells revealed the critical roles of 5-HT in regulating epithelial
homeostasis during involution, which is characterized by epi-
thelial tissue regression [5-7,40,41]. One expected effect of
elevated 5-HT activity in the normal breast is widespread
apoptotic cell death. Hence, we tested the effects of 5-HT on
apoptosis in mammary epithelial cells. The pHMEC and
MCF10A cells, as expected, showed significant increases in
active caspase 3 staining when treated with 5-HT, as com-
pared to untreated controls (Figure 5A). In contrast, all of the
breast cancer cell lines were highly resistant to 5-HT-induced
apoptosis under similar experimental conditions.
In response to 5-HT, MDA-MB-231 cells underwent dramatic
changes in their morphological phenotype, assuming exagger-
ated fibroblastic spindle morphologies (Figure 5B). In the
presence of 5-HT, the MDA-MB-231 cells projected long axial
appendages, which inconsistently contacted neighboring
cells, sometimes crossing cells without apparent interactions.
Previously, similar changes in morphology of MDA-MB-231
cells have been associated with exaggerated motility and inva-
siveness [42,43]. No similarly obvious phenotypic effects of 5-
HT treatment were observed in MCF10A, pHMEC, T47D or
MCF7 cells, suggesting that this response to 5-HT may be lim-
ited to the most aggressively-transformed breast cancer cells,
which have undergone an epithelial-mesenchymal transition
(Figure 5B).
Serotonin inhibits growth of untransformed human 
mammary epithelial cells via the 5-HT7 receptor
Because breast cancer cells were resistant to 5-HT-induced
apoptosis, we decided to explore its impact on proliferation in
these cells. Treatment with 5-HT for 36 h (in serum-containing
medium) resulted in significant inhibition of proliferation in both
pHMECs (approximately 55%) and MCF10A (approximately
37%), compared to untreated controls (Figure 6Ai and 6ii).
This observation was verified by a standard trypan blue assay
under similar experimental conditions [see Figure S5 in Addi-
tional data file 1]. Methysergide (MS), a broad spectrum 5-HT
receptor antagonist, attenuated growth inhibition by 5-HT in
pHMECs and MCF10A (Figure 6Ai and 6ii). Our previous
study showed that mammary epithelial cells express the 5-HT7
receptor [6] and stimulation of this receptor results in cyclic
AMP (cAMP)-mediated activation of both protein kinase A
(PKA) and p38 mitogen activated protein kinase (p38 MAPK)
[ 7 ] .  T r e a t m e n t  o f  M C F 1 0 A  c e l l s  w i t h  a  5 - H T 7  antagonist
(SB269970 [SB]) resulted in near complete extinction of 5-
HT inhibition of proliferation (Figure 6Aiii). In addition, specific
inhibition of p38 MAPK blocked the inhibition of proliferation
(Figure 6Aiv), however PKA inhibition had no significant effect
on proliferation. These data suggest that 5-HT7-mediated p38
MAPK activation may, in part, be responsible for growth inhib-
itory actions of 5-HT in mammary epithelial cells.
Breast cancer cells are refractory to the growth inhibitory 
response to 5-HT
It seemed paradoxical that breast cancer cell lines had an
increased capacity for 5-HT biosynthesis (Figure 1), while 5-
HT acted as a growth-inhibitor in mammary epithelial cells (Fig-
ure 6A). The juxtaposition of these findings suggested that the
breast cancer cells might be resistant to growth inhibition by
5-HT. Hence, we tested the effect of 5-HT on proliferation of
breast cancer cells. Confirming the previous result, 5-HT, in a
concentration dependent manner, inhibited proliferation of
mammary epithelial cells (pHMECs and MCF10A) (Figure
6B). However, breast cancer cells (T47D and MDA-MB-231)
responded differently to 5-HT. The T47D cells were resistant
to 5-HT, which required five- to ten-fold higher concentrations
to show growth inhibition (Figure 6Bi). However, MDA-MB-
231 cells were not only resistant to growth inhibition, but also,
were significantly stimulated by 5-HT at low concentrations
(Figure 6Aii). The altered response of MDA-MB-231 cells to 5-
HT was seen in spite of the presence of strong expression of
the HTR7 (Figure 4A and 4Bvi). To determine whether differ-
ences in cell death could account for the effects of 5-HT on
proliferation, we measured lactate dehydrogenase (LDH) lev-
els in the media, which is indicative of lysed/dead cells. In both
the MCF10A and MDA-MB-231 cells, the LDH levels in the
media remained unchanged by 36 h after 5-HT treatment [see
Figure S6 in Additional data file 1]. At later time points (72 h,
see Figure 5), there was substantial apoptosis in the untrans-
formed (i.e., MCF10A) cells and pHMECs, which implied that
these cells underwent growth arrest early, followed by apopto-
sis if 5-HT signaling was sustained.
Altered 5-HT7 signaling in human breast cancer cells
Given that growth inhibition by 5-HT occurs through the 5-HT7
receptor, resistance to growth inhibition in breast cancer cells
could be explained by: 1] a loss of 5-HT7 receptor expression
(Figure 4A and 4Bvi), 2] expression of 5-HT receptors that
counteract 5-HT7 (that is, Gi-coupled), (Figure 4A, Bii and
6Biii) or 3] changes in signaling downstream of 5-HT7; and
these possibilities are not mutually exclusive. Expression of
HTR7 in MDA-MB-231 cells was greater that in pHMEC and
MCF10A, yet MDA-MB-231 cells showed significant differ-
ences in their response to 5-HT (Figure 6Bii). Therefore, we
sought to determine whether Gs-coupled signaling, which is
downstream of 5-HT7, was altered in MDA-MB-231. As previ-
ously described [6], MCF10A cells showed a 5-HT concentra-
tion-dependent increase in cAMP accumulation (Figure 6Biii).
In MDA-MB-231 cells, the maximum cAMP activation wasBreast Cancer Research    Vol 11 No 6    Pai et al.
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Figure 5
5-HT influence on apoptosis and morphological transition in breast cells 5-HT influence on apoptosis and morphological transition in breast cells. (A) Staining for apoptosis marker cleaved caspase-3 (green), counter-
stained for nuclei (blue) for the indicated cells with or without 5-HT (7.5 × 10-4 M) treatment for 72 h in serum free media. (B) Phase-contrast images 
of the indicated cells with or without 5-HT (7.5 × 10-4 M) treatment for 72 h. Arrowheads point to appendages at intersections between adjacent 
cells.Available online http://breast-cancer-research.com/content/11/6/R81
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Figure 6
Growth inhibition by 5-HT in non-transformed human mammary epithelial cells is via 5-HT7 recepto, r and breast cancer cells are refractory to growth  inhibition by 5-HT Growth inhibition by 5-HT in non-transformed human mammary epithelial cells is via 5-HT7 recepto, r and breast cancer cells are refractory to growth 
inhibition by 5-HT. (Ai-iv) Proliferation assay (MTT) for detecting growth of primary human mammary epithelial cells (pHMECs) (Ai) and MCF10A 
(Aii-iv) after a period of 36 h following indicated treatments. Graphs are plotted as percent change from control (Ctrl - untreated) group. Error bars 
represent ± SEM. ***P < 0.001 (one-way ANOVA). (Ai and Aii), depict indicated cells treated with 5-HT (7.5 × 10-4 M) in presence or absence of 
broad-spectrum 5-HT receptor antagonist methysergide (MS) (60 μM). (Aiii) depicts MCF10A cells treated with 5-HT (7.5 × 10-4 M) in presence or 
absence of specific 5-HT7 receptor antagonist SB 269970 (SB) (80 μM). (Aiv) depicts MCF10A cells treated with 5-HT (7.5 × 10-4 M) in presence 
or absence of specific inhibitors of signaling proteins p38 MAPK (SB203580 [p38I]) (20 μM) and PKA (H89 [PKAI]) (10 μM). (Bi-ii) depict a prolif-
eration assay (MTT-viable count) for detecting cell growth after 36 h of treatment with indicated 5-HT concentrations. Graphs are plotted as percent 
change from respective controls (untreated group). Error bars represent ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 (Two-way ANOVA). (Bi) 
depicts comparison of pHMECs (grey bars) and T47D (black bars) cells response to indicated 5-HT concentrations. (Bii) depicts comparison of 
MCF10A (grey bars) and MDA-MB-231 (black bars) cells response to indicated 5-HT concentrations. (Biii) depicts measurements of intracellular 
cAMP accumulation in MCF10A (grey squares and line) and MDA-MB-231 (black triangle and line) cells in response to 5-HT stimulation as indi-
cated. Error bars in Biii represent ± SEM. ** P < 0.01, *** P < 0.001 (Two way ANOVA).Breast Cancer Research    Vol 11 No 6    Pai et al.
Page 12 of 17
(page number not for citation purposes)
observed at low concentrations of 5-HT, followed by a pro-
gressive decline in cAMP to levels below that of controls. Peak
cAMP accumulation was identical in both cells (Figure 6Biii).
These data imply altered signaling events associated with 5-
HT7.
Discussion
Regulation of mammary epithelium involves processes such as
epithelial proliferation, invasion of stroma and epithelial regres-
sion accompanied by extracellular matrix remodeling. Dysreg-
ulation of such epithelial regulatory mechanisms are critically
involved in the progression of breast cancers [17,18,42,44-
46]. The series of studies reported here were undertaken to
establish whether there are functionally-relevant associations
between local mammary 5-HT signaling and breast cancers.
The simple expedient of identifying serotonergic elements by
profiling of either mutations or gene expression was not appli-
cable to this problem because of the complexity of the 5-HT
receptor systems. This receptor complexity, and the multiple
mechanisms by which the ligand concentration is regulated,
make it possible for either normal or cancer cells to evolve
completely different sets of signaling interactions to achieve
common ends. This characteristic amounts to convergent evo-
lution of signaling among cancers, and it required us to use a
hypothesis-driven set of approaches, combined with hypothe-
sis-driven data mining.
In our previous studies, we showed that the mammary epithe-
lium expresses the TPH1 gene, which is induced during preg-
nancy, lactation and milk stasis at the onset of involution [5].
Here we have shown by immunostaining that TPH1 is present
primarily in the epithelial tissue of mammary glands. An early
finding that piqued our interest in the 5-HT system in human
breast cancer was the observation that representative breast
cancer cell lines showed significantly elevated TPH1 tran-
script and protein levels. These results were confirmed by
staining for TPH1 protein, which showed uniform and elevated
TPH1 expression among cancer cell lines. The shift of TPH1
gene expression from the normal tightly-regulated in vivo pat-
tern to a state of homogeneous overexpression in breast can-
cer cells was reminiscent of the general up-regulation of ER in
estrogen-sensitive breast cancer cells [47,48]. Whereas ER
and PR expression are positively correlated in breast cancers
an interesting observation was no effect of PR status on TPH1
levels. However, it has been reported that PR can be inde-
pendently regulated in breast cancers [49,50]. Hence, it is
likely that TPH1 is regulated by ER independent of PR status.
Since TPH1 is rate limiting for 5-HT synthesis in mammary epi-
thelial cells, as in other systems [6], breast cancer cells syn-
thesize excess 5-HT, which they may use to support their
growth advantages.
To gain insights into the nature of the 5-HT system in human
breast tumors, we used tissue microarray and data-mining
approaches. Increased TPH1 expression in cancer cell lines
was confirmed on the microarray specimens. An important
insight was the observation that there was not a simple linear
association between TPH1 expression and cancer stage.
Although TPH1 expression was suppressed in primary tumors
at early stages, it was increased later in progression. Corre-
spondingly, all of the tissue microarray specimens were har-
vested from the primary tumor sites of cancers at different
stages, but the breast cancer cell lines, which expressed ele-
vated TPH1, were all established from metastasized cells.
Therefore, the rebound of TPH1 expression associated with
progression may result in metastatic cells that express the
highest levels of TPH1.
Carcinogenesis is a complex multistep process, occurring
hand-in-hand with metastatic progression. For a normal epi-
thelial cell, there are many internal and external checks and
balances that guard against transformation and progression,
including cell senescence, apoptosis, appropriate stress
responses, and dependence on growth factors and differenti-
ating agents [3,51]. The growth inhibitory effect of 5-HT in the
non-transformed mammary epithelium is mediated, in part,
through 5-HT7 receptor signaling. The growth suppression
response to 5-HT is supported by our previous observations in
TPH1-/- mice, which showed accelerated mammary growth
upon prolactin stimulation, and impaired regression during
milk stasis [5].
There was a wide variety of changes in 5-HT receptor expres-
sion among the cancer specimens and database results. The
convergent nature of cancer evolution, in which there are sev-
eral routes for cancer cells to take while they accumulate
advantageous physiological alterations, provides a context for
understanding the diversity of these changes. Down-regula-
tion of 5-HT7 (Gs-coupled), which mediates growth inhibition
in untransformed cells, is one route to gain a growth advan-
tage. This particular alteration was seen in MCF7 and T47D
cells, and in ER negative and p53-wildtype tumor specimens.
Other routes to achieve growth advantage include a) suppres-
sion of 5-HT7 action through induction of Gi-coupled recep-
tors, such as 5-HT1E and 1F; b) induction of growth stimulatory
5-HT2C (Gq/11-coupled) [52,53] (observed in MCF7, T47D
and in human breast tumors); and c) downregulation of 5-HT
synthesis itself, as observed in early stages of primary tumor
growth. An important observation was the identical 5-HT
receptor expression pattern in both examples of untrans-
formed cells (MCF10A and pHMECs). This indicates that in
untransformed mammary epithelial cells, 5-HT receptor
expression is under tight control, whereas the control of 5-HT
receptor expression was aberrant in all breast cancer cells.
Sonier et al., [54] previously reported expression of 5-HT2A in
MCF7 cells, but we did not observe expression of this recep-
tor in either MCF7 or other breast cancer cells. Given the
degree to which receptor expression is labile in breast cancer
cells, it is conceivable that the subline in their lab is different
from the cells we received from ATCC.Available online http://breast-cancer-research.com/content/11/6/R81
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One intriguing finding was that 5-HT stimulated higher prolif-
eration rates in MDA-MB-231 cells and promoted obvious
morphological changes. Similar phenotypic changes have
been correlated with induction of a highly invasive behavior in
these cells [42,43].
Proliferative actions of 5-HT are not unprecedented and have
been reported to be crucial for liver regeneration [55]. Consid-
ering that sustained exposure to 5-HT induces quiescence
and apoptosis in untransformed mammary epithelial cells, the
response of MDA-MB-231 cells represents a major change in
the way these cells interpret the 5-HT signal. This proliferative
effect of 5-HT occurs in spite of the continued expression of
the 5-HT7 receptor, but we have not yet been able to attribute
the growth-stimulatory effect to a single 5-HT receptor. The
failure of 5-HT to cause growth inhibition and cell death in
MDA-MB-231 cells may be attributable to altered downstream
5-HT7 signaling. Changes in cAMP dynamics similar to those
we observed in MDA-MB-231 cells have been linked to a
switch from growth inhibition to growth stimulation in other
cells [56-61].
Although some of the normal physiological actions mediated
by 5-HT7 such as anti-proliferation and pro-apoptosis would
inhibit tumor progression, it is not a simple matter that 5-HT7
is uniformly tumor-suppressing. Other actions mediated by 5-
HT7 can enhance tumor progression. Among these is the dis-
ruption of cell-to-cell junctions [6,7], which provides an impor-
tant physiological advantage during invasion and metastasis.
Tight junctions have been shown to restrain tumorgenesis, and
disrupting tight junctions and other static cell junctions is
imperative for tumor growth and invasion [62,62-67].
Figure 7
Model of a working hypothesis for 5-HT influences on breast cancer progression Model of a working hypothesis for 5-HT influences on breast cancer progression. 5-HT is a tumor-suppressing signal in non-transformed breast cells 
and early stage breast cancers, so early tumor growth relies on reductions in TPH1 expression. During tumor progression, cells acquire genetic or 
epigenetic alterations in 5-HT signaling which then make them resistant to suppressive 5-HT actions and favor tumor-promoting actions (e.g., 
dynamic cell junctions and cell shedding), as well as acquisition of new receptors and functions (e.g., stimulated proliferation and epithelial-mesen-
chymal transition). The figure is inspired by the image in [69].Breast Cancer Research    Vol 11 No 6    Pai et al.
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Although 5-HT signaling can expose cancer cells to a mixture
of positive and negative consequences, cancer cells cannot
simplify their environment by avoiding 5-HT signaling com-
pletely. Apart from the fact of endogenous epithelial 5-HT bio-
synthesis, cancer cells receive 5-HT signaling from at least
three outside sources: neighboring normal breast tissue, nor-
mal blood circulation, and hemostatic plaques within tumors
(platelet activation and 5-HT release - an essential part of sta-
bilizing the tumor vasculature) [68]. Consequently, there are
advantages for breast cancer cells to be gained from altering,
rather than avoiding, 5-HT signaling. Presumably, these advan-
tages explain why TPH1 expression does not simply continue
to decline to zero in advanced cancers, and is commonly ele-
vated in the most highly-transformed cancer cells. Analogous
nonlinear associations with breast cancer progression have
been reported in the TGF-β system, which is also generally
cytostatic in normal cells but advantageous in advanced can-
cers [69,70].
While the epithelial cells of breast cancer may be important
targets of 5-HT, it is also likely that stromal elements, including
connective tissue, adipose, infiltrating blood cells, and vascu-
lar elements, are regulated by 5-HT synthesized in breast can-
cers. The discrepancy between the 5-HT receptor expression
profiles of primary mammary epithelial cells (5-HT1D,2B,3 and 7)
and in normal whole gland tissue (5-HT1B,1D,1F, 2A, 2B,3,5A and
7, Oncomine database) suggests that a subset of 5-HT recep-
tors (5-HT1F,2A,5A) are expressed in non-epithelial elements
(connective tissue, myopepithelium, blood cells, adipose tis-
sue, vasculature). Some of these extra-epithelial tissues are
well known targets of 5-HT (blood vessels and adipose), and
others, such as the connective tissue stroma, have not yet
been studied. A new study [71] has shown that 5-HT is an
important physiological suppressor of osteoblast growth and
bone mineralization. Therefore, bone, to which breast cancers
preferentially metastasize, may use breast cell-derived 5-HT as
an important extra-epithelial target tissue.
Our previous [5-7] and current results are summarized (Figure
7) as follows: a) physiological responses to 5-HT include
some that are tumor-suppressing (growth inhibition and apop-
tosis) and others that are tumor-promoting (junctional break-
down, cell shedding) and because of the growth suppression
actions, early tumor growth relies on reductions in TPH1
expression and 5-HT synthesis, and b) as the tumors progress,
cells acquire alterations in the 5-HT signal, thus developing
resistance to the tumor-suppressive aspects of 5-HT (growth
inhibition and apoptosis), while retaining and favoring tumor-
promoting actions. These effects are further enhanced by
increasing TPH1 levels and acquisition of new tumor promot-
ing-activities (cell proliferation, survival, epithelial-mesenchy-
mal transition phenotype). Fully optimized 5-HT signaling in
cancers results in tumors in which 5-HT is used to promote
growth, invasiveness, angiogenesis and other patho-physio-
logical effects. While this understanding may need many
refinements, it is further supported by the overall trend toward
increased complexity of 5-HT receptor expression in associa-
tion with aggressive tumors, which suggests beneficial influ-
ences of 5-HT on tumor progression.
Importantly, we believe the implications of understanding 5-HT
physiology extend beyond breast cancers. This is based on
reports indicating important roles of 5-HT in the cancers of
skin, gut, brain, lung, prostate, liver, and pancreas [20-
23,27,28]. Duct systems that are lined by epithelia and require
homeostatic regulation represents a common denominator
among these organ systems. In some of these organs, like
breast and liver, 5-HT has been implicated in homeostatic reg-
ulation of secretory ducts [19,29,72].
Conclusions
Although cancers generally are clonal and may rely on self-
renewing stem cells over the long term [3,45,73-76], any given
tumor must become heterotypic if it is to reach a substantial
size and pathophysiologic complexity. The cancer consists of
a community of cells that contribute different pathophysiologi-
cal properties. The heterotypic nature of a cancer is responsi-
ble for its ability to adapt to a changing microenvironment
during progression through invasiveness and metastasis.
Among the different cell types within a cancer, there are pre-
sumably differences in the components and functionality of the
5-HT system. Such differences include cells with a greater or
lesser ability to synthesize 5-HT, and cells with different com-
plements of receptors. While this heterotypic 5-HT physiology
in breast tumors may create a great deal of complexity, it is
possible that future studies will identify common features or
weak links in the 5-HT system of breast cancers, which can be
exploited therapeutically. The inherent druggability of 5-HT
systems makes it reasonable to assume that treatments target-
ing these systems could achieve sufficiently positive therapeu-
tic indices to justify their uses in cancer.
It would be premature to suggest that studies reported here
are sufficient to establish the prognostic or therapeutic value
of the breast cancer TPH1/5-HT system. However, an early
prediction from our studies is that tumors in which TPH1 is sig-
nificantly downregulated will have not yet gained resistance to
5-HT or reached metastatic stages. Therefore, TPH1 down-
regulation may indicate a better prognosis. Through further
studies on the breast 5-HT system we expect to improve our
understating of its role in breast cancer.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
VPP and NDH designed research, VPP performed research,
AMM, LLH. and ARB provided analytical and technical sup-
port. NDH and VPP wrote the paper. All authors read and
approved the manuscript.Available online http://breast-cancer-research.com/content/11/6/R81
Page 15 of 17
(page number not for citation purposes)
Additional files
Acknowledgements
The work was supported by grants from the National Institutes of Health 
(DK52134) and Department of the Army (BC052576) (NDH) and Post-
doctoral fellowship (T32-CA059268) to L.L.H. This project was sup-
ported by National Research Initiative Competitive Grant no: 2007-
35206-17898 from the USDA Cooperative State Research, Education 
and Extension Service. The authors declare no conflict of interest. The 
authors would like to thank Elise Demitrack for help preparing the man-
uscript.
References
1. Polyak K: Breast cancer: origins and evolution.  J Clin Invest
2007, 117:3155-3163.
2. Polyak K, Haviv I, Campbell IG: Co-evolution of tumor cells and
their microenvironment.  Trends Genet 2009, 25:30-38.
3. Hanahan D, Weinberg RA: The hallmarks of cancer.  Cell 2000,
100:57-70.
4. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F,
Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic
therapy elicits malignant progression of tumors to increased
local invasion and distant metastasis.  Cancer Cell 2009,
15:220-231.
5. Matsuda M, Imaoka T, Vomachka AJ, Gudelsky GA, Hou Z, Mistry
M, Bailey JP, Nieport KM, Walther DJ, Bader M, Horseman ND:
Serotonin regulates mammary gland development via an
autocrine-paracrine loop.  Dev Cell 2004, 6:193-203.
6. Stull MA, Pai V, Vomachka AJ, Marshall AM, Jacob GA, Horseman
ND: Mammary gland homeostasis employs serotonergic reg-
ulation of epithelial tight junctions.  Proc Natl Acad Sci USA
2007, 104:16708-16713.
7. Pai VP, Horseman ND: Biphasic Regulation of Mammary Epi-
thelial Resistance by Serotonin through Activation of Multiple
Pathways.  J Biol Chem 2008, 283:30901-30910.
8. Hernandez LL, Stiening CM, Wheelock JB, Baumgard LH,
Parkhurst AM, Collier RJ: Evaluation of serotonin as a feedback
inhibitor of lactation in the bovine.  J Dairy Sci 2008,
91:1834-1844.
9. Hadsell DL, Parlow AF, Torres D, George J, Olea W: Enhance-
ment of maternal lactation performance during prolonged lac-
tation in the mouse by mouse GH and long-R3-IGF-I is linked
to changes in mammary signaling and gene expression.  J
Endocrinol 2008, 198:61-70.
10. Park M, Kang K, Park S, Back K: Conversion of 5-hydroxytryp-
tophan into serotonin by tryptophan decarboxylase in plants,
Escherichia coli, and yeast.  Biosci Biotechnol Biochem 2008,
72:2456-2458.
11. Callera G, Tostes R, Savoia C, Muscara MN, Touyz RM: Vasoac-
tive peptides in cardiovascular (patho)physiology.  Expert Rev
Cardiovasc Ther 2007, 5:531-552.
12. Mohammad-Zadeh LF, Moses L, Gwaltney-Brant SM: Serotonin:
a review.  J Vet Pharmacol Ther 2008, 31:187-199.
13. Crowell MD, Wessinger SB: 5-HT and the brain-gut axis: oppor-
tunities for pharmacologic intervention.  Expert Opin Investig
Drugs 2007, 16:761-765.
14. Dale GL: Coated-platelets: an emerging component of the pro-
coagulant response.  J Thromb Haemost 2005, 3:2185-2192.
15. Cote F, Thevenot E, Fligny C, Fromes Y, Darmon M, Ripoche MA,
Bayard E, Hanoun N, Saurini F, Lechat P, Dandolo L, Hamon M,
Mallet J, Vodjdani G: Disruption of the nonneuronal tph1 gene
demonstrates the importance of peripheral serotonin in car-
diac function.  Proc Natl Acad Sci USA 2003,
100:13525-13530.
16. Lesurtel M, Soll C, Graf R, Clavien PA: Role of serotonin in the
hepato-gastroIntestinal tract: an old molecule for new per-
spectives.  Cell Mol Life Sci 2008, 65:940-952.
17. Russo J, Russo IH: Toward a physiological approach to breast
cancer prevention.  Cancer Epidemiol Biomarkers Prev 1994,
3:353-364.
18. Mallon E, Osin P, Nasiri N, Blain I, Howard B, Gusterson B: The
basic pathology of human breast cancer.  J Mammary Gland
Biol Neoplasia 2000, 5:139-163.
19. Marzioni M, Glaser S, Francis H, Marucci L, Benedetti A, Alvaro D,
Taffetani S, Ueno Y, Roskams T, Phinizy JL, Venter J, Fava G, Les-
age GD, Alpini G: Autocrine/paracrine regulation of the growth
of the biliary tree by the neuroendocrine hormone serotonin.
Gastroenterology 2005, 128:121-137.
20. Alpini G, Invernizzi P, Gaudio E, Venter J, Kopriva S, Bernuzzi F,
Onori P, Franchitto A, Coufal M, Frampton G, Alvaro D, Lee SP,
Marzioni M, Benedetti A, DeMorrow S: Serotonin metabolism is
dysregulated in cholangiocarcinoma, which has implications
for tumor growth.  Cancer Res 2008, 68:9184-9193.
21. Vicentini LM, Cattaneo MG, Fesce R: Evidence for receptor sub-
type cross-talk in the mitogenic action of serotonin on human
small-cell lung carcinoma cells.  Eur J Pharmacol 1996,
318:497-504.
22. Siddiqui EJ, Shabbir M, Mikhailidis DP, Thompson CS, Mumtaz
FH:  The role of serotonin (5-hydroxytryptamine1A and 1B)
receptors in prostate cancer cell proliferation.  J Urol 2006,
176:1648-1653.
23. Sreevidya CS, Khaskhely NM, Fukunaga A, Khaskina P, Ullrich SE:
Inhibition of photocarcinogenesis by platelet-activating factor
or serotonin receptor antagonists.  Cancer Res 2008,
68:3978-3984.
24. Suzuki A, Naruse S, Kitagawa M, Ishiguro H, Yoshikawa T, Ko SB,
Yamamoto A, Hamada H, Hayakawa T: 5-Hydroxytryptamine
Strongly Inhibits Fluid Secretion in Guinea Pig Pancreatic Duct
Cells.  J Clin Invest 2001, 108:749-756.
25. Nathan JD, Liddle RA: Neurohormonal control of pancreatic
exocrine secretion.  Curr Opin Gastroenterol 2002, 18:536-544.
26. Russo F, Vittoria A: Neuroendocrine cells in the vestibular
glands of the genital tract of cows and pigs.  Acta Histochem
2006, 108:351-355.
27. Ogawa T, Sugidachi A, Tanaka N, Fujimoto K, Fukushige J, Tani Y,
Asai F: Effects of R-102444 and its active metabolite R-96544,
selective 5-HT2A receptor antagonists, on experimental acute
and chronic pancreatitis: Additional evidence for possible
involvement of 5-HT2A receptors in the development of exper-
imental pancreatitis.  Eur J Pharmacol 6544, 521:156-163.
28. Siddiqui EJ, Thompson CS, Mikhailidis DP, Mumtaz FH: The role
of serotonin in tumour growth (review).  Oncol Rep 2005,
14:1593-1597.
29. Van Lommel A: Pulmonary neuroendocrine cells (PNEC) and
neuroepithelial bodies (NEB): chemoreceptors and regulators
of lung development.  Paediatr Respir Rev 2001, 2:171-176.
30. Ethier SP, Summerfelt RM, Cundiff KC, Asch BB: The influence
of growth factors on the proliferative potential of normal and
The following Additional files are available online:
Additional file 1
PDF document containing Table S1, primers used for 
detecting 5-HT receptors; Figure S1, which compares 
SERT protein levels between non-transformed and 
breast cancer cells; Figure S2 is TPH1 staining intensity 
key for scoring tissue microarray sections; Figure S3 
represents changes in TPH1 signal in human breast 
tumors; Figure S4 represents differences in 5-HT 
receptor isoform gene expression between non-
transformed (pHMECs and MCF10A) and breast cancer 
cells (MCF7, MDA-MB-231 and T47D; Figure S5 
depicts 5-HT inhibition of cell growth in non-transformed 
mammary epithelial cells; and Figure S6 shows that the 
5-HT effect on cell proliferation at 36 h is not influenced 
by cell death.
See http://www.biomedcentral.com/content/
supplementary/bcr2448-S1.PDFBreast Cancer Research    Vol 11 No 6    Pai et al.
Page 16 of 17
(page number not for citation purposes)
primary breast cancer-derived human breast epithelial cells.
Breast Cancer Res Treat 1991, 17:221-230.
31. The National Cancer Institute-Cooperative Breast Cancer Tis-
sue   [http://cbctr.nci.nih.gov/]
32. Huang Y, Li X, Jiang J, Frank SJ: Prolactin modulates phosphor-
ylation, signaling and trafficking of epidermal growth factor
receptor in human T47D breast cancer cells.  Oncogene 2006,
25:7565-7576.
33. Tonner E, Barber MC, Travers MT, Logan A, Flint DJ: Hormonal
control of insulin-like growth factor-binding protein-5 produc-
tion in the involuting mammary gland of the rat.  Endocrinology
1997, 138:5101-5107.
34. McCarty KS Jr, Miller LS, Cox EB, Konrath J, McCarty KS Sr:
Estrogen receptor analyses. Correlation of biochemical and
immunohistochemical methods using monoclonal antirecep-
tor antibodies.  Arch Pathol Lab Med 1985, 109:716-721.
35. Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson
JF, Macmillan D, Blamey RW, Ellis IO: High-throughput protein
expression analysis using tissue microarray technology of a
large well-characterised series identifies biologically distinct
classes of breast cancer confirming recent cDNA expression
analyses.  Int J Cancer 2005, 116:340-350.
36. Rhodes DR, Kalyana-Sundaram S, Mahavisno V, Varambally R, Yu
J, Briggs BB, Barrette TR, Anstet MJ, Kincead-Beal C, Kulkarni P,
Varambally S, Ghosh D, Chinnaiyan AM: Oncomine 3.0: genes,
pathways, and networks in a collection of 18,000 cancer gene
expression profiles.  Neoplasia 2007, 9:166-180.
37. Oncomine database   [http://www.oncomine.org]
38. Nilsson T, Longmore J, Shaw D, Pantev E, Bard JA, Branchek T,
Edvinsson L: Characterisation of 5-HT receptors in human cor-
onary arteries by molecular and pharmacological techniques.
Eur J Pharmacol 1999, 372:49-56.
39. Kato S, Kumamoto H, Hirano M, Akiyama H, Kaneko N: Expres-
sion of 5-HT2A and 5-HT1B receptor mRNA in blood vessels.
Mol Cell Biochem 1999, 199:57-61.
40. Motyl T, Gajkowska B, Zarzynska J, Gajewska M, Lamparska-Przy-
bysz M: Apoptosis and autophagy in mammary gland remode-
ling and breast cancer chemotherapy.  J Physiol Pharmacol
2006, 57(Suppl 7):17-32.
41. Stein T, Salomonis N, Gusterson BA: Mammary gland involution
as a multi-step process.  J Mammary Gland Biol Neoplasia
2007, 12:25-35.
42. Bemis LT, Schedin P: Reproductive state of rat mammary gland
stroma modulates human breast cancer cell migration and
invasion.  Cancer Res 2000, 60:3414-3418.
43. McDaniel SM, Rumer KK, Biroc SL, Metz RP, Singh M, Porter W,
Schedin P: Remodeling of the mammary microenvironment
after lactation promotes breast tumor cell metastasis.  Am J
Pathol 2006, 168:608-620.
44. Schedin P, O'Brien J, Rudolph M, Stein T, Borges V: Microenvi-
ronment of the involuting mammary gland mediates mammary
cancer progression.  J Mammary Gland Biol Neoplasia 2007,
12:71-82.
45. Polyak K: Breast cancer: origins and evolution.  J Clin Invest
2007, 117:3155-3163.
46. Howard BA, Gusterson BA: Human breast development.  J
Mammary Gland Biol Neoplasia 2000, 5:119-137.
47. Clarke RB, Howell A, Potten CS, Anderson E: Dissociation
between steroid receptor expression and cell proliferation in
the human breast.  Cancer Res 1997, 57:4987-4991.
48. Jarzabek K, Koda M, Kozlowski L, Mittre H, Sulkowski S, Kottler
ML, Wolczynski S: Distinct mRNA, protein expression patterns
and distribution of oestrogen receptors alpha and beta in
human primary breast cancer: correlation with proliferation
marker Ki-67 and clinicopathological factors.  Eur J Cancer
2005, 41:2924-2934.
49. Hewitt SC, Korach KS: Progesterone action and responses in
the alphaERKO mouse.  Steroids 2000, 65:551-557.
50. Lange CA: Challenges to defining a role for progesterone in
breast cancer.  Steroids 2008, 73:914-921.
51. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F,
Inoue M, Bergers G, Hanahan D, Casanovas O: Antiangiogenic
therapy elicits malignant progression of tumors to increased
local invasion and distant metastasis.  Cancer Cell 2009,
15:220-231.
52. Westphal RS, Sanders-Bush E: Differences in agonist-inde-
pendent and -dependent 5-hydroxytryptamine2C receptor-
mediated cell division.  Mol Pharmacol 1996, 49:474-480.
53. De Lucchini S, Ori M, Nardini M, Marracci S, Nardi I: Expression
of 5-HT2B and 5-HT2C receptor genes is associated with pro-
liferative regions of Xenopus developing brain and eye.  Brain
Res Mol Brain Res 2003, 115:196-201.
54. Sonier B, Arseneault M, Lavigne C, Ouellette RJ, Vaillancourt C:
The 5-HT2A serotoninergic receptor is expressed in the MCF-
7 human breast cancer cell line and reveals a mitogenic effect
of serotonin.  Biochem Biophys Res Commun 2006,
343:1053-1059.
55. Lesurtel M, Graf R, Aleil B, Walther DJ, Tian Y, Jochum W, Gachet
C, Bader M, Clavien PA: Platelet-derived serotonin mediates
liver regeneration.  Science 2006, 312:104-107.
56. Bombik BM, Burger MM: c-AMP and the cell cycle: inhibition of
growth stimulation.  Exp Cell Res 1973, 80:88-94.
57. Burger MM, Bombik BM, Breckenridge BM, Sheppard JR: Growth
control and cyclic alterations of cyclic AMP in the cell cycle.
Nat New Biol 1972, 239:161-163.
58. Sheppard JR: Difference in the cyclic adenosine 3',5'-mono-
phosphate levels in normal and transformed cells.  Nat New
Biol 1972, 236:14-16.
59. Ryan WL, Heidrick ML: Inhibition of cell growth in vitro by ade-
nosine 3',5'-monophosphate.  Science 1968, 162:1484-1485.
60. Ryan WL, Heidrick ML: Role of cyclic nucleotides in cancer.  Adv
Cyclic Nucleotide Res 1974, 4:81-116.
61. Heidrick ML, Ryan WL: Adenosine 3',5'-cyclic monophosphate
and contact inhibition.  Cancer Res 1971, 31:1313-1315.
62. Birchmeier W: E-cadherin as a tumor (invasion) suppressor
gene.  Bioessays 1995, 17:97-99.
63. Itoh M, Bissell MJ: The organization of tight junctions in epithe-
lia: implications for mammary gland biology and breast tumor-
igenesis.  J Mammary Gland Biol Neoplasia 2003, 8:449-462.
64. Hoevel T, Macek R, Mundigl O, Swisshelm K, Kubbies M: Expres-
sion and targeting of the tight junction protein CLDN1 in
CLDN1-negative human breast tumor cells.  J Cell Physiol
2002, 191:60-68.
65. Swisshelm K, Machl A, Planitzer S, Robertson R, Kubbies M,
Hosier S: SEMP1, a senescence-associated cDNA isolated
from human mammary epithelial cells, is a member of an epi-
thelial membrane protein superfamily.  Gene 1999,
226:285-295.
66. Hoover KB, Liao SY, Bryant PJ: Loss of the tight junction
MAGUK ZO-1 in breast cancer: relationship to glandular differ-
entiation and loss of heterozygosity.  Am J Pathol 1998,
153:1767-1773.
67. Chlenski A, Ketels KV, Korovaitseva GI, Talamonti MS, Oyasu R,
Scarpelli DG: Organization and expression of the human zo-2
gene (tjp-2) in normal and neoplastic tissues.  Biochim Biophys
Acta 2000, 1493:319-324.
68. Ho-Tin-Noe B, Goerge T, Cifuni SM, Duerschmied D, Wagner DD:
Platelet granule secretion continuously prevents intratumor
hemorrhage.  Cancer Res 2008, 68:6851-6858.
69. Roberts AB, Wakefield LM: The two faces of transforming
growth factor beta in carcinogenesis.  Proc Natl Acad Sci USA
2003, 100:8621-8623.
70. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL: p38 mitogen-
activated protein kinase is required for TGFbeta-mediated
fibroblastic transdifferentiation and cell migration.  J Cell Sci
2002, 115:3193-3206.
71. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schutz G,
Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R,
Ducy P, Karsenty G: Lrp5 controls bone formation by inhibiting
serotonin synthesis in the duodenum.  Cell 2008,
135:825-837.
72. Bayer H, Muller T, Myrtek D, Sorichter S, Ziegenhagen M, Nor-
gauer J, Zissel G, Idzko M: Serotoninergic receptors on human
airway epithelial cells.  Am J Respir Cell Mol Biol 2007,
36:85-93.
73. Polyak K: Is breast tumor progression really linear?  Clin Can-
cer Res 2008, 14:339-341.
74. Nowell PC: The clonal evolution of tumor cell populations.  Sci-
ence 1976, 194:23-28.
75. Ginestier C, Wicha MS: Mammary stem cell number as a deter-
minate of breast cancer risk.  Breast Cancer Res 2007, 9:109.Available online http://breast-cancer-research.com/content/11/6/R81
Page 17 of 17
(page number not for citation purposes)
76. Chang CC: Recent translational research: stem cells as the
roots of breast cancer.  Breast Cancer Res 2006, 8:103.
77. Richardson AL, Wang ZC, De Nicolo A, Lu X, Brown M, Miron A,
Liao X, Iglehart JD, Livingston DM, Ganesan S: X chromosomal
abnormalities in basal-like human breast cancer.  Cancer Cell
2006, 9:121-132.
78. Expression Project for Oncology - Breast Samples   [http://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE2109]
79. Yu K, Ganesan K, Miller LD, Tan P: A modular analysis of breast
cancer reveals a novel low-grade molecular signature in estro-
gen receptor-positive tumors.  Clin Cancer Res 2006,
12:3288-3296.
80. Ivshina AV, George J, Senko O, Mow B, Putti TC, Smeds J, Lindahl
T, Pawitan Y, Hall P, Nordgren H, Wong JE, Liu ET, Bergh J,
Kuznetsov VA, Miller LD: Genetic reclassification of histologic
grade delineates new clinical subtypes of breast cancer.  Can-
cer Res 2006, 66:10292-10301.
81. Miller WR, Larionov AA, Renshaw L, Anderson TJ, White S, Murray
J, Murray E, Hampton G, Walker JR, Ho S, Krause A, Evans DB,
Dixon JM: Changes in breast cancer transcriptional profiles
after treatment with the aromatase inhibitor, letrozole.  Phar-
macogenet Genomics 2007, 17:813-826.
82. Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide
J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M,
Birnbaum D, Bertucci F: Prognosis and gene expression profil-
ing of 20q13-amplified breast cancers.  Clin Cancer Res 2006,
12:4533-4544.
83. van 't Veer LJ, Dai H, Vijver MJ van de, He YD, Hart AA, Mao M,
Peterse HL, Kooy K van der, Marton MJ, Witteveen AT, Schreiber
GJ, Kerkhoven RM, Roberts C, Linsley PS, Bernards R, Friend SH:
Gene expression profiling predicts clinical outcome of breast
cancer.  Nature 2002, 415:530-536.
84. Chin SF, Teschendorff AE, Marioni JC, Wang Y, Barbosa-Morais
NL, Thorne NP, Costa JL, Pinder SE, Wiel MA van de, Green AR,
Ellis IO, Porter PL, Tavare S, Brenton JD, Ylstra B, Caldas C: High-
resolution aCGH and expression profiling identifies a novel
genomic subtype of ER negative breast cancer.  Genome Biol
2007, 8:R215.
85. Minn AJ, Gupta GP, Siegel PM, Bos PD, Shu W, Giri DD, Viale A,
Olshen AB, Gerald WL, Massague J: Genes that mediate breast
cancer metastasis to lung.  Nature 2005, 436:518-524.
86. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia
JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, Rouzier R,
Sneige N, Ross JS, Vidaurre T, Gomez HL, Hortobagyi GN, Pusztai
L: Pharmacogenomic predictor of sensitivity to preoperative
chemotherapy with paclitaxel and fluorouracil, doxorubicin,
and cyclophosphamide in breast cancer.  J Clin Oncol 2006,
24:4236-4244.
87. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren
H, Farmer P, Praz V, Haibe-Kains B, Desmedt C, Larsimont D, Car-
doso F, Peterse H, Nuyten D, Buyse M, Vijver MJ Van de, Bergh J,
Piccart M, Delorenzi M: Gene expression profiling in breast can-
cer: understanding the molecular basis of histologic grade to
improve prognosis.  J Natl Cancer Inst 2006, 98:262-272.
88. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F,
Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, Jatkoe T,
Berns EM, Atkins D, Foekens JA: Gene-expression profiles to
predict distant metastasis of lymph-node-negative primary
breast cancer.  Lancet 2005, 365:671-679.
89. Desmedt C, Piette F, Loi S, Wang Y, Lallemand F, Haibe-Kains B,
Viale G, Delorenzi M, Zhang Y, d'Assignies MS, Bergh J, Lidereau
R, Ellis P, Harris AL, Klijn JG, Foekens JA, Cardoso F, Piccart MJ,
Buyse M, Sotiriou C, TRANSBIG Consortium: Strong time
dependence of the 76-gene prognostic signature for node-
negative breast cancer patients in the TRANSBIG multicenter
independent validation series.  Clin Cancer Res 2007,
13:3207-3214.
90. Farmer P, Bonnefoi H, Becette V, Tubiana-Hulin M, Fumoleau P,
Larsimont D, Macgrogan G, Bergh J, Cameron D, Goldstein D,
Duss S, Nicoulaz AL, Brisken C, Fiche M, Delorenzi M, Iggo R:
Identification of molecular apocrine breast tumours by micro-
array analysis.  Oncogene 2005, 24:4660-4671.
91. Vijver MJ van de, He YD, van't Veer LJ, Dai H, Hart AA, Voskuil DW,
Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma
D, Witteveen A, Glas A, Delahaye L, Velde T van der, Bartelink H,
Rodenhuis S, Rutgers ET, Friend SH, Bernards R: A gene-
expression signature as a predictor of survival in breast can-
cer.  N Engl J Med 2002, 347:1999-2009.
92. Bild AH, Yao G, Chang JT, Wang Q, Potti A, Chasse D, Joshi MB,
Harpole D, Lancaster JM, Berchuck A, Olson JA Jr, Marks JR,
Dressman HK, West M, Nevins JR: Oncogenic pathway signa-
tures in human cancers as a guide to targeted therapies.
Nature 2006, 439:353-357.